Mark G. Frattini

Roswell Park Comprehensive Cancer Center — United States

Medicine · Health Sciences

35h-index11.2kcitations155works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(58), Chronic Myeloid Leukemia Treatments(21), CAR-T cell therapy research(19), Chronic Lymphocytic Leukemia Research(18), DNA Repair Mechanisms(17)

Publications155 total

Thioguanine and decitabine can overcome hypomethylating agent resistance in patients with advanced myeloid malignancies
Blood·2025Open Access
Longitudinal single-cell spatial proteomics reveals predictive immune and stem cell signatures in Relapsed/Refractory AML
Blood·2025Open Access
Corrigendum to: Antiproliferative Activity of Cephalotaxus Esters:Overcoming Chemoresistance
Combinatorial Chemistry & High Throughput Screening·2025
2490P Identification of pathogenic germline variants by germline-focused tumour analysis in a European study of high-risk and advanced prostate cancer patients
Annals of Oncology·2025
Unraveling the Role of Leukotriene A4 Hydrolase in Hepatocellular Carcinoma: Implications for Targeted Therapy and Tumor Progression
Digestive Diseases and Sciences·2025
Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance
Combinatorial Chemistry & High Throughput Screening·2024· 1 cited
Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance in Cancer Therapy
2023Open Access
Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Blood·2023· 14 cited
Unraveling Novel Mechanisms for Targeting the Intra-S-Phase Checkpoint in p53-Mutated Acute Myeloid Leukemia
Blood·2023Open Access
Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Blood·2023· 14 cited
P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
HemaSphere·2023· 9 citedOpen Access
NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL)
Hematological Oncology·2023Open Access
Data from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
Supplementary Data from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
Supplementary Figures from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
Supplementary Data from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
Supplementary Methods from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
Supplementary Methods from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
Supplementary Figures from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
Data from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Courtney D. DiNardo(13), Hagop M. Kantarjian(12), Eytan M. Stein(8), Joseph G. Jurcic(7), Martin S. Tallman(7), P. Maslak(6), David A. Scheinberg(6), Andrew H. Wei(6), Marina Konopleva(6), Daniel A. Pollyea(6), Laimonis A. Laimins(6), Stéphane de Botton(6), Kyle J. MacBeth(6), Amir T. Fathi(6), Todd Rosenblat(5), Keith W. Pratz(5), Hartmut Döhner(5), Frederik Lersch(5), Bin Wu(5), Amer M. Zeidan(5)